Dahlia Salman

Dahlia Salman is a skilled professional with extensive experience in the fields of analytical chemistry and pharmaceutical sciences. Currently serving as Chief Executive Officer at Bioxhale since May 2021, Dahlia leads the development of advanced breath analysers for early disease detection and precision medicine. Dahlia's academic contributions include a role as Senior Lecturer at De Montfort University and previous positions at Nottingham Trent University. Additionally, Dahlia is a committee member of the Joint Analytical Pharmaceutical Group, enhancing collaborative efforts in analytical research. Prior experience includes postdoctoral research at Loughborough University, focusing on novel breath biomarkers, and significant contributions to optimizing chemotherapy treatments at The Royal Marsden NHS Foundation Trust. Dahlia holds a PhD in Oncology Pharmacy Practice-Pharmaceutical Analysis from Kingston University, complemented by a Master’s in Pharmaceutical Science and Management and a Bachelor’s in Pharmaceutical Sciences from the same institution.